The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Open accessAbstract
BACKGROUND: Plasma triglyceride levels are heritable and are correlated with the risk of coronary heart disease. Sequencing of the protein-coding regions of the human genome (the exome) has the potential to identify rare mutations that have a large effect on phenotype. METHODS: We sequenced the protein-coding regions of 18,666 genes in each of 3734 participants of European or African ancestry in the Exome Sequencing Project. We conducted tests to determine whether rare mutations in coding sequence, individually or in aggregate within a gene, were associated with plasma triglyceride levels. For mutations associated with triglyceride levels, we subsequently evaluated their association with the risk of coronary heart disease in 110,970 persons. RESULTS: An aggregate of rare mutations in the gene encoding apolipoprotein C3 (APOC3) was associated with lower plasma triglyceride levels. Among the four mutations that drove this result, three were loss-of-function mutations: a nonsense mutation (R19X) and two splice-site mutations (IVS2+1G→A and IVS3+1G→T). The fourth was a missense mutation (A43T). Approximately 1 in 150 persons in the study was a heterozygous carrier of at least one of these four mutations. Triglyceride levels in the carriers were 39% lower than levels in noncarriers (P<1×10(-20)), and circulating levels of APOC3 in carriers were 46% lower than levels in noncarriers (P=8×10(-10)). The risk of coronary heart disease among 498 carriers of any rare APOC3 mutation was 40% lower than the risk among 110,472 noncarriers (odds ratio, 0.60; 95% confidence interval, 0.47 to 0.75; P=4×10(-6)). CONCLUSIONS: Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease. (Funded by the National Heart, Lung, and Blood Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, loss-of-function mutations in APOC3, which encodes apolipoprotein C-III, result in significantly lower plasma TG levels and confer a 40–50% lower risk of ischemic cardiovascular events [25].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with loss-of-function mutations in APOC-III exhibit significantly reduced levels of triglycerides and remnant cholesterol, along with a nearly 40% reduction in ASCVD risk [32, 33].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Individuals with genetic loss-of-function mutations in the APOC3 gene exhibit markedly lower TG levels and reduced incidence of CAD, highlighting apoC-III as a compelling therapeutic target for HTG and associated complications [25, 29, 43].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, with genetic studies supporting the role of several novel therapeutic targets (eg, apo C-III and ANGPTL3) in atherosclerosis, ongoing clinical trials using RNA interference therapy (antisense oligonucleotides and small interfering RNAs) have the potential to further inform our understanding of the triglyceride-based atherosclerotic pathways (120,121).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [120]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [64]
In the citing paper
“ApoCIII has been identified as a potentially important new risk factor. 104-106”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Robust relationship inference in genome-wide association studies
Manichaikul, A., Mychaleckyj, J. C., Rich, S. S., Daly, K., Sale, M., & Chen, W.-M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq559 · Cited by 3,541
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Research works printed but not linked: 1
- Taylor HA, 2005, Ethn Dis, 15, S4
Cited by
Sorted by citations
Items 301–400 of 1,001
Wang, H., Huang, X., Xu, P., Liu, X., Zhou, Z., Wang, F., Li, J., Wang, Y., Xian, X., Liu, C., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154740 · Cited by 42
Bays, H. E., Ballantyne, C. M., Doyle, R. T., Juliano, R. A., & Philip, S. (2016) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2016.07.007 · Cited by 43
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 43
The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
Hartiala, J., Schwartzman, W. S., Gabbay, J., Ghazalpour, A., Bennett, B. J., & Allayee, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0641-6 · Cited by 44
Emdin, C. A., Khera, A. V., Aragam, K. G., Haas, M. E., Chaffin, M. D., Klarin, D. M., Natarajan, P., Bick, A. G., Zekavat, S. M., Nomura, A., et al. (2018) · Diabetes · doi:10.2337/db18-0857 · Cited by 42
Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death
Natarajan, P., Collier, T., Jin, Z., Lyass, A., Li, Y., Ibrahim, N. E., Mukai, R., McCarthy, C. P., Massaro, J. M., D’Agostino, R. B., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.073 · Cited by 45
Developing Medicines That Mimic the Natural Successes of the Human Genome
Kathiresan, S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.049 · Cited by 43
Jattan, J., Rodia, C. N., Li, D., Diakhate, A., Dong, H., Bataille, A. M., Shroyer, N. F., & Kohan, A. B. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071340 · Cited by 43
Wang, Y., Shen, L., & Xu, D. (2018) · Clinical Cardiology · doi:10.1002/clc.23104 · Cited by 52
Implementation of public health genomics in Pakistan
Riaz, M., Tiller, J. M., Ajmal, M., Azam, M., Qamar, R., & Lacaze, P. A. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0428-z · Cited by 42
Dai, W., Zhang, Z., Yao, C., & Zhao, S. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1166-5 · Cited by 44
The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 43
Paiva, A. A., Raposo, H. F., Wanschel, A. C. B. A., Nardelli, T. R., & Oliveira, H. C. F. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1838679 · Cited by 41
Novel Therapeutic Targets for Managing Dyslipidemia
Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 42
ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis
Capoulade, R., Torzewski, M., Mayr, M., Chan, K., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Burnap, S. A., et al. (2020) · Heart · doi:10.1136/heartjnl-2019-315840 · Cited by 41
Davidson, W. S., Cooke, A. L., Swertfeger, D. K., & SHAH, A. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00925-4 · Cited by 41
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40
Treatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
Human knockout research: new horizons and opportunities
Alkuraya, F. S. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.11.003 · Cited by 41
Severe hypertriglyceridemia: Existing and emerging therapies
Malick, W. A., Do, R., & Rosenson, R. S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108544 · Cited by 45
Koekemoer, A. L., Codd, V., Masca, N. G. D., Nelson, C. P., Musameh, M. D., Kaess, B. M., Hengstenberg, C., Rader, D. J., & Samani, N. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309201 · Cited by 40
Olkkonen, V. M., Sinisalo, J. P., & Jauhiainen, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.019 · Cited by 41
Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
Fogacci, F., Norata, G. D., Toth, P. P., Arca, M., & Cicero, A. F. G. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00836-w · Cited by 42
Johansen, M. Ø., Nielsen, S. F., Afzal, S., Vedel‐Krogh, S., Smith, G. D., & Nordestgaard, B. G. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa290 · Cited by 42
The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.003 · Cited by 40
Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits
Yan, H., Niimi, M., Matsuhisa, F., Zhou, H., Kitajima, S., Chen, Y., Wang, C., Yang, X., Yao, J. Q., Yang, D., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314368 · Cited by 39
Hussain, A., Sun, C., Selvin, E., Nambi, V., Coresh, J., Jia, X., Ballantyne, C. M., & Hoogeveen, R. C. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa152 · Cited by 39
The effect of phenotypic outliers and non-normality on rare-variant association testing
Auer, P. L., Reiner, A. P., & Leal, S. M. (2016) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.270 · Cited by 40
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Sundaram, M., Curtis, K. R., Alipour, M. A., LeBlond, N. D., Margison, K. D., Yaworski, R., Parks, R. J., McIntyre, A. D., Hegele, R. A., Fullerton, M. D., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m077313 · Cited by 40
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 42
Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants
Wang, H., Liu, Z., Shao, J., Jiang, M., Lu, X.-C., Lin, L., Wang, L., Xu, Q., Zhang, H. S., Li, X., et al. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.11.003 · Cited by 45
Zha, Y., Lu, Y., Zhang, T., Yan, K., Zhuang, W., Liang, J., Cheng, Y., & Wang, Y. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01605-7 · Cited by 38
Calcaterra, I. L., Lupoli, R., Minno, A. D., & Minno, M. N. D. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13841 · Cited by 38
Musunuru, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.002 · Cited by 38
Zuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 38
Implications of reverse cholesterol transport: Recent studies
Levinson, S. S., & Wagner, S. G. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.018 · Cited by 36
Opportunities and Challenges in Cardiovascular Pharmacogenomics
Roden, D. M., Driest, S. L. V., Wells, Q. S., Mosley, J. D., Denny, J. C., & Peterson, J. F. (2018) · Circulation Research · doi:10.1161/circresaha.117.310965 · Cited by 38
Goyal, S., Tanigawa, Y., Zhang, W., Chai, J. F., Almeida, M., Sim, X., Lerner, M. R., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01531-8 · Cited by 40
Han, Y. Y., Dorajoo, R., Chang, X., Wang, L., Khor, C. C., Sim, X., Cheng, C., Shi, Y., Tham, Y. C., Zhao, W., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-18214-z · Cited by 38
Remnant lipoproteins and atherosclerotic cardiovascular disease
Tada, H., Nohara, A., Inazu, A., Mabuchi, H., & Kawashiri, M.-A. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.12.014 · Cited by 37
Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
Malick, W. A., Waksman, O., Do, R., Köenig, W., Pradhan, A. D., Stroes, E. S. G., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.034 · Cited by 38
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 41
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 39
Reeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 40
Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies
Dib, I., Khalil, A., Chouaib, R., El-Makhour, Y., & Noureddine, H. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06071-5 · Cited by 37
Lali, R., Chong, M., Omidi, A., Mohammadi‐Shemirani, P., Le, A., Cui, E., & Paré, G. (2021) · Nature Communications · doi:10.1038/s41467-021-26114-0 · Cited by 38
Safety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
Bruikman, C. S., Stoekenbroek, R. M., Hovingh, G. K., & Kastelein, J. J. P. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.010 · Cited by 38
APOC3 siRNA and ASO therapy for dyslipidemia
Chebli, J., Larouche, M., & Gaudet, D. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000857 · Cited by 35
Orho‐Melander, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12407 · Cited by 39
Chan, Y., & Ramji, D. P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_1 · Cited by 41
Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review
Fu, Q., Hu, L., Shen, T., Yang, R., & Jiang, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226773 · Cited by 41
History and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34
Secondary hypertriglyceridemia in children and adolescents
Blackett, P. R., Wilson, D. P., & McNeal, C. J. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.04.006 · Cited by 35
Targeting ApoC-III to Reduce Coronary Disease Risk
Khetarpal, S. A., Qamar, A., Millar, J. S., & Rader, D. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0609-y · Cited by 34
Personalized Management of Cardiovascular Disorders
Jain, K. K. (2017) · Medical Principles and Practice · doi:10.1159/000481403 · Cited by 37
Okada, T., Ohama, T., Takafuji, K., Kanno, K., Matsuda, H., Sairyo, M., Zhu, Y., Saga, A., Kobayashi, T., Masuda, D., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.002 · Cited by 33
Kegulian, N. C., Ramms, B., Horton, S. B., Trenchevska, O., Nedelkov, D., Graham, M. J., Lee, R. G., Esko, J. D., Yassine, H. N., & Gordts, P. L. S. M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312723 · Cited by 36
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 39
Amor, A. J., Serra‐Mir, M., Martínez‐González, M. Á., Corella, D., Salas‐Salvadó, J., Fitó, M., Estruch, R., Serra‐Majem, L., Arós, F., Babió, N., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004803 · Cited by 37
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 34
GWAS as a Driver of Gene Discovery in Cardiometabolic Diseases
Atanasovska, B., Kumar, V., Fu, J., Wijmenga, C., & Hofker, M. H. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.10.004 · Cited by 32
Aroner, S. A., Yang, M., Li, J., Furtado, J. D., Sacks, F. M., Tjønneland, A. M., Overvad, K., Cai, T., & Jensen, M. K. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx143 · Cited by 34
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
Shrestha, P., van de Sluis, B., Dullaart, R. P. F., & van den Born, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.12.001 · Cited by 34
Dietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII
Hieronimus, B., & Stanhope, K. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000653 · Cited by 33
Model-based assessment of replicability for genome-wide association meta-analysis
McGuire, D., Jiang, Y., Liu, M., Weissenkampen, J. D., Eckert, S., Yang, L., Chen, F., Liu, M., Jiang, Y., Wedow, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21226-z · Cited by 30
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 40
MARAIS, D. P. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000192 · Cited by 33
Association of Triglyceride-Related Genetic Variants With Mitral Annular Calcification
Afshar, M. S., Luk, K., Do, R., Dufresne, L., Owens, D. S., Harris, T. B., Peloso, G. M., Kerr, K. F., Wong, Q., Smith, A. V., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.051 · Cited by 33
CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia
Chadwick, A. C., & Musunuru, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309326 · Cited by 33
Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia
Khetarpal, S. A., Wang, M., & Khera, A. V. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1912350 · Cited by 33
Therapeutic targets of triglyceride metabolism as informed by human genetics
Bauer, R. C., Khetarpal, S. A., Hand, N. J., & Rader, D. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.005 · Cited by 32
Gene editing for dyslipidemias: New tools to “cut” lipids
Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 34
Ghafouri, K. J., Cooney, J., Bedford, D. K., Wilson, J., CASLAKE, M. J., & Gill, J. M. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1196 · Cited by 34
Nagiec, M. M., Skepner, A. P., Negri, J. M., Eichhorn, M., Kuperwasser, N., Comer, E., Muncipinto, G., Subramanian, A., Clish, C. B., Musunuru, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120295 · Cited by 31
Bays, H. E., Hallén, J., Vige, R., Fraser, D. A., Zhou, R., Hustvedt, S. O., Orloff, D. G., & Kastelein, J. J. P. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.012 · Cited by 32
van Leeuwen, E. M., Sabo, A., Bis, J. C., Huffman, J. E., Manichaikul, A. W., Smith, A. V., Feitosa, M. F., Demissie, S., Joshi, P. K., Duan, Q., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103439 · Cited by 34
Hsueh, W.-C., Nair, A. K., Kobes, S., Chen, P., Göring, H. H. H., Pollin, T. I., Malhotra, A., Knowler, W. C., Baier, L. J., & Hanson, R. L. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001809 · Cited by 32
Yingchun, H., Ma, Y., Wen, J., He, X., & Xiaohong, Z. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0867-5 · Cited by 35
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 33
Importance of Genetic Studies of Cardiometabolic Disease in Diverse Populations
Fernández‐Rhodes, L., Young, K. L., Lilly, A. G., Raffield, L. M., Highland, H. M., Wojcik, G. L., Agler, C. S., Love, S.-A. M., Okello, S., Petty, L. E., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.315893 · Cited by 33
Hu, Y., Chen, C., Wang, Y., Yang, W., Wang, Y., Zhu, W., Yan, C., & Liu, P. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153467 · Cited by 31
Kristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 33
Sanllorente, A., Soria-Florido, M. T., Castañer, O., Lassale, C. M., Salas‐Salvadó, J., Martínez‐González, M. Á., Subirana, I., Ros, E., Corella, D., Estruch, R., et al. (2021) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab246 · Cited by 32
Morton, A. M., Furtado, J. D., Lee, J., Amerine, W., Davidson, M. H., & Sacks, F. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.005 · Cited by 32
Mensah, G. A., Kiley, J. P., Mockrin, S. C., Lauer, M. S., Hoots, W. K., Patel, Y., Cook, N. L., Patterson, A. P., & Gibbons, G. H. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302605 · Cited by 32
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
Leveraging human genetics to guide drug target discovery
Stitziel, N. O., & Kathiresan, S. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.08.008 · Cited by 31
Rogers, M. A., Chen, J., Nallamshetty, S., Pham, T., Goto, S., Muehlschlegel, J. D., Libby, P., Aikawa, M., Aïkawa, E., & Plutzky, J. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313366 · Cited by 33
Cao, Y., Zhang, H., Jin, J., Liu, H., Zhang, Y., Xu, R., Gao, Y., Guo, Y., Zhu, C., Hua, Q., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000746 · Cited by 31
Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review
Toth, P. P., Shah, P. K., & Lepor, N. E. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100086 · Cited by 35
Ahmed, L., Butler, A. E., Dargham, S. R., Latif, A., Chidiac, O. M., Atkin, S. L., & Khalil, C. A. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00641-1 · Cited by 32
Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury
Schunk, S. J., Hermann, J., Sarakpi, T., Triem, S., Lellig, M., Hahm, E., Zewinger, S., Schmit, D., Becker, E., Möllmann, J., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021040503 · Cited by 31
Cardiovascular pharmacogenomics: current status and future directions
Roden, D. M. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.78 · Cited by 32
Skulas-Ray, A. C., Alaupovic, P., Kris-Etherton, P. M., & West, S. G. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.12.001 · Cited by 30
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 31
Chapman, M. J., Packard, C. J., Björnson, E., Ginsberg, H. N., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120529 · Cited by 36
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 35
Metadata
- Authors
- The TG and HDL Working Group of the Exome Sequencing Project, N. H.
- Corresponding author
- The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 22-31
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4180269
- OpenAlex
- W2170009139
- Semantic Scholar
- b3c2b9d4976782980ff38a64e223209866004dcc
- Cited by
- 1,071
- References
- 66
- Citations by year
- 2026: 52 · 2025: 73 · 2024: 48 · 2023: 56 · 2022: 75 · 2021: 93 · 2020: 110 · 2019: 90 · 2018: 81 · 2017: 113 · 2016: 132 · 2015: 107 · 2014: 41
- FWCI
- 89.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- U.S. Department of Agriculture
- Massachusetts General Hospital (R01HL107816)
- University of Wisconsin-Milwaukee
- George Washington University
- University of Washington
- Donovan Family Foundation
- University of Ottawa
- Norges Teknisk-Naturvitenskapelige Universitet
- Queen Mary University of London
- Wellcome Trust
- Deutsches Zentrum für Herz-Kreislaufforschung
- Università degli Studi di Milano
- University of Texas Health Science Center at Houston
- Broad Institute
- Russell and Diana Hawkins Family Foundation
- National Institute for Health and Care Research (NF-SI-0611-10170)
- British Heart Foundation
- University of Leicester
- University of Oxford
- University of Leeds
- Fondation Leducq (T32HL007208)
- Lunds Universitet
- Hjärt-Lungfonden
- King Abdulaziz University
- Universität zu Lübeck
- Umeå Universitet
- Technische Universität München
- Università degli Studi di Verona
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339, NNF14OC0011049)
- Regione Emilia-Romagna
- National Institutes of Health (1rc2hl103010-01)
- School of Medicine, Stanford University
- University of North Carolina at Chapel Hill
- Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai
- Canadian Institutes of Health Research
- Medical Research Council
- Barts and The London School of Medicine and Dentistry
- Helmholtz Zentrum München
- National Institute on Aging (P30AG010129, U01AG049505)
- National Heart, Lung, and Blood Institute (HL 102923, RC2HL102925, HL-102924, K08HL114642, RC2HL102926, RC2HL102923, RC2HL-103010, HL 103010, RC2HL102924, R01HL107816, T32HL007208, R01HL109946)
- National Cancer Institute (R01CA082659)
- National Institute of Neurological Disorders and Stroke (R01NS017950)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein C-III, loss-of-function mutations, plasma triglycerides, coronary artery disease, rare variants, splice site mutation, nonsense mutation, missense mutations, genetic risk, European ancestry, African ancestry
- MeSH terms
- Coronary Disease, Genotype, Heterozygote, Humans, Liver, Mutation, Risk Factors, Triglycerides, Sequence Analysis, DNA, Black People, White People, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
